Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer
October 07 2021 - 8:05AM
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics
contract development and manufacturing organization (CDMO) working
to improve patient lives by providing high quality development and
manufacturing services to biotechnology and pharmaceutical
companies, today announced the appointment of Matthew Kwietniak as
chief commercial officer. Mr. Kwietniak is an accomplished senior
global sales executive with a proven track record of driving
revenue growth and delivering sustainable results through the
building and management of successful sales teams, as well as the
establishment and expansion of key client relationships. In his new
role, he will be responsible for continuing the current growth
trajectory of Avid’s CDMO business through the ongoing expansion of
the company’s commercial and clinical client base.
Mr. Kwietniak most recently served as head of
drug product sales for the Americas within the pharma services
group at Thermo Fisher Scientific. In this role, he led the North
America team of sales leaders and business development executives
for the company’s pharmaceutical development and commercial
manufacturing business. At Thermo Fisher Scientific, Mr. Kwietniak
is credited with record sales growth and consistent overachievement
of quarterly and annual goals during his tenure and leadership. He
also spent over a decade as a senior sales executive in the
clinical development services business at Covance, Inc., a division
of LabCorp. Throughout his time with Covance, Mr. Kwietniak held
multiple escalating sales leadership roles, culminating in a
three-year tenure as executive director of sales in the clinical
development services division. In this role, he expanded and
managed a U.S. commercial team of business development directors
that included the signing of several large Phase III contracts. In
his leadership career, he has been responsible for growing and
supporting sales teams generating in excess of $1 billion annually.
Mr. Kwietniak has also achieved success in key sales manager and
sales representative positions for VWR International (now
Avantor).
“We are very pleased to welcome Matt to Avid and
believe that he will serve as an excellent leader for our active
and talented business development team. His demonstrated ability to
lead successful sales teams and drive sustained revenue growth will
serve the company well as we continue to increase capacity through
multiple facility expansion projects,” said Nicholas Green,
president and chief executive officer of Avid Bioservices. “We are
particularly impressed by Matt’s ability to lead teams that focus
on simultaneously winning new client business, expanding current
customer relationships and importantly building partnerships, which
have and will continue to be key as we grow the Avid brand and
Avid’s business.”
About Avid Bioservices,
Inc.
Avid Bioservices is a dedicated contract
development and manufacturing organization (CDMO) focused on
development and CGMP manufacturing of biopharmaceutical drug
substances derived from mammalian cell culture. The company
provides a comprehensive range of process
development, CGMP clinical and commercial manufacturing
services for the biotechnology and biopharmaceutical industries.
With 28 years of experience producing monoclonal antibodies and
recombinant proteins, Avid's services
include CGMP clinical and commercial drug substance
manufacturing, bulk packaging, release and stability testing and
regulatory submissions support. For early-stage programs the
company provides a variety of process development activities,
including upstream and downstream development and optimization,
analytical methods development, testing and characterization. The
scope of our services ranges from standalone process development
projects to full development and manufacturing programs through
commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024